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Organ Donation and Transplantation in Latvia
Ieva Ziedina, MD, PhD,1,2 Janis Jushinskis, MD, PhD,1,2 Sandra Lejniece, MD, PhD,1,3  
and Eva Strike, MD, PhD1,2
Latvia is a country located in Northern Europe bor-dering the Baltic Sea (Figure 1). In 2018, Latvia cel-
ebrated a 100 years since as an independent state. Riga, 
Latvia’s capital and the biggest city in the Baltics, was 
founded already in 1201.
The World War II brought occupation under both, Ger-
man and Soviets, and de-facto freedom was only regained 
in 1991. Joining NATO and the European Union (EU) 
in 2004 have been recent historic events. The population 
of Latvia has declined from 2.5 to 1.9 million since the 
independence from the Soviet Union. Unique in the EU, 
the majority of researchers (52%) in Latvia is female.2The 
2018 annual GNP was € 29.4 billion. With a growth rate 
of 4.8%, Latvia is a leader among EU countries.3
TRANSPLANT ACTIVITIES
Solid organ transplantation started in 19734 with live 
donor kidney transplantation (father to his 15-y-old 
daughter) at Pauls Stradins Clinical University Hospital in 
Riga. This institution remains the only organ transplanta-
tion center in Latvia and is currently offering adult kid-
ney, pancreas, heart, and liver transplants in addition to 
pediatric kidney and heart transplants; lung and intestinal 
transplants are currently not offered in Latvia. Riga East 
Clinical University Hospital is performing bone marrow.
LEGAL FRAMEWORK OF ORGAN DONATION
The law “On the Protection of the Body of Deceased 
Human Beings and the Use of Human Tissues and Organs 
in Medicine” has been adopted in 1992,5 only a year 
after the de-facto independence from the Soviet Union. 
Deceased donation in Latvia is based on a presumed con-
sent with the possibility to register as a “nondonor”. Even 
though the legal framework is clear, family consent is usu-
ally obtained before organ procurement.
SOLID ORGAN TRANSPLANTATION
Deceased organ donor rates have dropped from 17.3 
pmp in 2000 to 12.3 pmp in 2017.6 There are approxi-
mately 6 donors pmp after cardiocirculatory death (DCD) 
annually. Living donor kidney transplants have been reini-
tiated in 2007 and rates have increased up to 6.7 pmp in 
20176 (Figure 2). Close to three quarters (74%) of living 
donors are genetically related, the majority being par-
ents; the remaining 26% of living donors are emotionally 
related, the majority being spouses. To raise awareness for 
organ donation, Latvia is participating in the EU project on 
“Training and social awareness for increasing organ dona-
tion in the EU and neighboring countries”. Since 2017, 
transplant coordinators are localized in all university hos-
pitals in Riga in addition to major regional hospitals.
As of January 2019, 2023 kidney, 27 heart, 4 pancreas, 
and 7 liver transplants have been performed in Latvia.
The incidence of renal replacement therapy has pla-
teaued during the last years with approximately 97 pmp 
(2015).7 The prevalence of patients on renal replacement 
therapy in Latvia has increased at the same time (from 
450 pmp in 2013 to 540 pmp in 2018). In absolute num-
bers, there have been 1058 patients on renal replacement 
therapy in 2017 including 55% with a functioning kidney 
transplant, 36% have been on hemo-, and 9% on perito-
neal dialysis.
Annually, 12% of all patients on dialysis are listed for 
kidney transplantation. Pre-emptive kidney transplants 
are rare. Historically, most kidney transplants have been 
from deceased donors; however, recently live donor kidney 
transplants have increased rapidly. While live donor kid-
ney transplants contributed with only 8% in 2012, rates 
have increased to 25% in 2017.6 It is worth noting that 
the live donor kidney transplant program that started in 
1973 had been on hold as deceased donor transplant rates 
had increased. However, with a drop of deceased kidney 
donors from 18.7 pmp in 2007 to 13 pmp in 2008, the live 
donor kidney program has been reactivated reaching 6.7 
pmp in 2017.6
Kidney transplants from living donors across HLA bar-
riers have been performed since 2011; ABO-incompatible 
kidney transplantations since 2012. The protocol for ABO 
incompatible transplantation includes a single dose of 
rituximab (300 mg/m2) and plasmapheresis or immunoad-
sorption aiming at anti-ABO titers of less than 1:8. Living 
kidney donor exchange programs started in May 2013 and 
have thus far been carried out as paired donations.
Delayed graft functions in deceased donor kidney trans-
plants vary from 10% to 30% and are mainly linked to 
donor age and prolonged ischemia. Biopsy proven acute 
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rejection rates had been as high as 30% but have dropped 
to 18% since utilizing tacrolimus as an initial maintenance 
immunosuppressant. Short and long-term graft and patient 
survival rates are comparable to other European countries; 
20% of all kidney transplantations are retransplantations.8
The heart transplant program in Latvia has started in 
2002 with rates of 0.5 pmp in 2017.6
The first successful liver transplantation in Latvia has 
been performed in 2011.6 Until 2017, liver transplant 
activities have been on a hiatus and patients had been 
listed at other European Centers (mainly Tartu, Estonia), 
returning to Latvia for post-transplant care. Liver trans-
plant activities resumed in 2018 at Paula Stradina Clinical 
University Hospital and 6 liver transplants (including one 
urgent retransplantation) have been performed thus far 
reaching 3.15 pmp.
The first simultaneous kidney–pancreas transplant has 
been performed in 2008;6 however, the procedure has 
been infrequent and there is currently no active program. 
Multivisceral or vascular composite tissue transplanta-
tions are currently not performed in Latvia.
Lifelong post-transplant immunosuppression is sup-
ported by the government.
BONE MARROW TRANSPLANTATION
Hematopoietic stem cell transplantation (HSCT) has 
been started in 2000 with the first autologous HSCT for a 
patient with non-Hodgkin’s lymphoma (NHL). High-dose 
chemotherapy in combination with autologous HSCT has 
been implemented in 2001. To date, 280 autologous HSCT 
have been performed for patients with NHL, Hodgkin’s 
disease, and multiple myeloma.
Autologous HSCT have been performed for the first 
time in 2019 for 2 patients with testicular nonseminoma 
and one patient with a connective tissue disease.
The first allogenic HSCT has been performed in 2006. 
Allogeneic HSCT in Latvia are limited to related donor/
recipients. Patients requiring a nonrelated donor or pedi-
atric recipients will need to travel abroad. Since 2006, 
30 allogenic HSCT have been performed in patients 
with acute leukemia (24), severe aplastic anemia (4), and 
chronic myeloid leukemia (2).
CHALLENGES AND OPPORTUNITIES
Transplant numbers continue to increase in Latvia. For 
many years, Latvia has participated in the donor network of 
the Baltic states (Balt-transplant). Recently, Estonia has joined 
Scandiatransplant and Latvia continues to cooperate for kid-
ney and heart donations with Lithuania. Close co-operations 
continue also with the National Center of Pathology, an 
Affiliate of Vilnius University Hospital Santaros Klinikos.
One of the main current challenges is the missing accred-
itation of our HLA laboratory by the European Federation 
for Immunogenetics. An achievement is our active living 
kidney donor exchange program.FIGURE 2. Deceased and living organ donor rates in Latvia pmp.
FIGURE 1. Location of Latvia in the European Union.1
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Research Highlights
Laura Barisoni1 and Xunrong Luo2
Clinical-grade Computational 
Pathology Using Weakly Supervised 
Deep Learning on Whole Slide Images
Campanella G, Hanna MG, Geneslaw L, et al. Nat Med. 
2019; 25:1301–1309.
Computational image analysis is an evolving field that relies on digital whole slide imaging and computer 
algorithms to create decision support tools for pathologists, 
clinicians, researchers, and patients. The immediate goal is to 
enhance the efficiency and accuracy of morphologic assess-
ment, while enabling generalizability, which should result in 
better global patient care. While this science has been operat-
ing for some time in radiology, it is in its infancy in pathol-
ogy. Generating such computer algorithms has so far relied 
on small, supervised (manually annotated) datasets for deep 
machine learning and training. The application of such algo-
rithms to large-scale unsupervised datasets, however, is often 
problematic due to wide variances of clinical samples typi-
cally not captured by small training datasets. In addressing 
this challenge, Campanella et al1 presented a new framework 
for training at a very large scale based on “multiple instance 
learning,” aiming to train a classification model in a weakly 
supervised manner. This process employs information from 
anatomic pathology laboratory information system and/or 
electronic health records, and involves the following several 
steps: (1) tiling of the entire slide image; (2) training at the tile 
level and ranking the tiles according to their probability of 
being positive; (3) integrating information across the entire 
slide using a recurrent neural network; and (4) correlating 
with or reporting the final classification result. To test the 
validity of this approach, the authors used a binary system 
(presence or absence of tumors on the whole slide images), 
with the goal of achieving 100% sensitivity while maximiz-
ing the area under the curve of the receiver operating charac-
teristic curve. Achieving 100% sensitivity would allow such 
an algorithm to be used as an effective digital screening tool, 
minimizing the work load of pathologists while not miss-
ing any potential positive cases. The authors tested 3 large 
datasets involving prostate cancer, basal cell carcinoma, and 
breast cancer metastasis to axillary lymph nodes, totaling 
44 732 whole slide images from 15 187 patients, all without 
any data curation, were tested. To further address generaliz-
ability, the datasets were provided by different sites with the 
use of different slide scanners. This framework achieved an 
area under the curve of >0.98 for all cancer types, excluding 
65%–75% of negative slides while retaining 100% sensitiv-
ity.
Such an approach could be applied to transplant clini-
cal care. For example, optimal caring for organ recipients 
is often critically dependent on our ability to timely detect 
immunological activities and accurately discern nature, 
mechanisms, and etiology of structural changes from 
implant, for cause or protocol biopsies.2 Implementing such 
a computational decision support system would therefore 
significantly enhance our efficiency and precision in our 
clinical practices. Thrre of the following advances of such a 
system would be highly advantageous for its application in 
transplantation: (1) deep learning annotation and classifi-
cation of tissue structural changes predictive of mechanisms 
and outcome; (2) algorithms that efficiently assess continu-
ous variables rather than binary outputs; and (3) the ability 
to report the final classification also as continuous, quan-
tifiable outputs. The framework demonstrated here exhib-
its the ability to train accurate classification models at an 
unprecedently large scale, providing a solid basis for future 
improvements, and development of computational decision 
support systems for practical clinical utilities.
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